Clinic - Diagnostic Aspects of Modern Biomarkers of Early Atherosclerosis and Fibrotic activity of Systemic Scleroderma
Asian Journal of Medical Principles and Clinical Practice,
Systemic sclerosis (SS) is a systemic disease with heterogeneous clinical manifestations of the skin and internal organs. It is believed that the triggering mechanism of its development is initial vascular damage, which leads to inflammatory reactions and the development of the accumulation of collagen and other components of the extracellular matrix. It goes without saying what a disease treatment is. Diagnosis of SS is carried out by clinical observation and using methods such as the Rodnan skin counter (mRSS), durometry, cutometry, and ultrasound determination of skin thickness. These methods are quite of thickness of intima complex (TIC) consuming and subjective. In addition, these methods do not provide information about the activity of the fibrotic process. These disadvantages of the listed methods can be compensated for by studying biomarkers that reflect the activity of inflammatory and fibrotic processes, but can be used to assess the prognosis and effectiveness of treatment. The aim of the review focuses on cardiac and fibrotic biomarkers of patients with scleroderma. These include growth factors, cytokines and proteases, their inhibitors, as well as proteins of the extracellular matrix, especially collagens, adapted to skin biopsies and in serum samples from patients with SS. Summarized information on non-invasive physical and laboratory studies is proposed, which provides a better understanding of cardiovascular disease and fibrotic activity, can be effectively used to assess the potential therapeutic response and help in choosing the opTICal treatment options for SS.
- Systemic sclerosis
- heart disease
- endothelial dysfunction.
How to Cite
Ayers NB, Sun CM, Chen SY. Transforming growth factor-signaling in systemic sclerosis. J. Biomed. Res. 2018;32(1):3-12.
DOI: 10.7555/ JBR.31.20170034.
Bosello S, de Santis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis: Safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res. Ther. 2010;12(2): 54.
Brinckmann J, Kim S, Wu J, et al. Interleukin 4 and prolonged hypoxia induce a higher gene expression of lysyl hydroxylase 2 and an altered cross-link pattern: Important pathogenetic steps in early and late stage of systemic scleroderma? Matrix Biol. 2005;24:459-468.
Costa S, Mondini M, Caneparo V, et al. Detectionof antiIFI16 antibodies by ELISA: Clinical and serological associations in systemic sclerosis. Rheumatol. 2011;50(4):674-681.
DOI: 10.1093/rheumatology/ keq372.
Ruaro B, Nallino MG, Casabella A, Salton F, Confalonieri P, De Tanti A, Bruni C. Monitoring the microcirculation in the diagnosis and follow-up of systemic sclerosis patients: Focus on pulmonary and peripheral vascular manifestations. Microcirculation; 2020.
Epub ahead of print.
Pizzorni C, Sulli A, Smith V, Ruaro B, Trombetta AC, Cutolo M, Paolino S. Primary Raynaud's phenomenon and nailfold videocapillaroscopy: Age-related changes in capillary morphology. Clin Rheumatol. 2017;36:1637-1642.
Smith V, Thevissen K, Trombetta AC, Pizzorni C, Ruaro B, Piette Y, Paolino S, De Keyser F, Sulli A, Melsens K, Cutolo M. Nailfold Capillaroscopy and clinical applications in Systemic Sclerosis. Microcirculation. 2016;105:119-24.
Farina G, Lafyatis D, Lemaire R, et al. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2010;62:580-588.
Farina G, Lafyatis D, Lemaire R, et al. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2010;62:580—588.
Fett N. Scleroderma: Nomenclature, etiology, pathogenesis, prognosis and treatments: Facts and controversies. Clin. Dermatol. 2013;31(4):432-437.
DOI: 10.1016/j. clindermatol.2013.01.010.
Gheita TA, Hussein H. Cartilage Oligomeric Matrix Protein (COMP) in Systemic Sclerosis (SSc): Role in disease severity and subclinical rheumatoid arthritis overlap. Joint Bone Spine. 2012;79:51-56.
Gourh P, Arnett FC, Tan FK, et al. Association of TNFSF4 (OX40L) polymorphisms with susceptibility to systemic sclerosis. Ann. Rheum. Dis. 2010;69(3):550-555.
Hasegawa M, Fujimoto M, Matsushita T, et al. Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clin. Rheum. 2011;30(2):231-237.
Iwata Y, Yoshizaki A, Ogawa F, et al. Increased serum pentraxin 3 in patients with systemic sclerosis. J. Rheumatol. 2009;36:976-983.
DOI: 10.3899/jrheum. 080343.
Kang T, Abignano G, Lettieri G, et al. Skin imaging in systemic sclerosis. Eur. J. Rheumatol. 2014;1(3):111-116.
Khan K, Xu S, Nihtyanova S, et al. Clinical and pathological significance of interleukin 6 over expression in systemic sclerosis. Ann. Rheum. Dis. 2012;71(7):1235-1242.
DOI: 10.1136/annrheumdis-2011- 200955.
Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): A phase 2, randomised, controlled trial. Lancet. 2016;387(10038):2630-2640.
Kim W-U, Min S-Y, Cho M-L, et al. Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. Arthritis Res. Ther. 2005;7:71-79.
DOI: 10.1186/ ar1454.
Knapinska AM, Estrada CA, Fields GB. The roles of matrix metalloproteinases in pancreatic cancer. Prog. Mol. Biol. Transl. Sci. 2017;148:339-354.
Kumánovics G, Péntek M, Bae S, et al. Assessment of skin involvement in systemic sclerosis. Rheumatol. 2017;56(5):53-66.
Lakota K, Wei J, Carns M, et al. Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: Potential utility as biomarker? Arthritis Res. Ther. 2012;14(3):102.
Le Huu D, Matsushita T, Jin G, et al. IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease. J. Invest Dermatol. 2012;132(12):2752—2761.
DOI: 10.1038/ jid.2012.226.
Leask A, Sunil K, Parapuram N, et al. Connective tissue growth factor (CTGF, CCN2) gene regulation: A potent clinical bio-marker of fibroproliferative disease? J. Cell Commun Signal. 2009;3(2):89- 94.
Li H, Furst DE, Jin H, et al. High-frequency ultrasound of the skin in systemic sclerosis: An exploratory study to examine correlation with disease activity and to define the minimally detectable difference. Arthritis Res. Ther. 2018;20:181.
Liu X, Mayes MD, Tan FK, et al. Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis. Arthritis and Rheumatism. 2013;65(1):226-235.
Makino K, Makino T, Stawski L, et al. Anti-connective tissue growth factor (CTGF/CCN2)monoclonal antibody attenuates skin fibrosis in mice models of systemic sclerosis. // Arthritis Res. Ther. 2017;19:(1):134.
Manetti M, Guiducci S, Romano E, et al. Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: Correlation with severity of skin and pulmonary fibrosis and vascular damage. Ann. Rheum. Dis. 2012;71:1064-1072.
DOI: 10.1136/ annrheumdis-2011-200837.
Matsushita T, Takehara K. An update on biomarker discovery and use in systemic sclerosis. Expert. Rev. Mol. Diagn. 2017;17(9):823-833.
DOI: 10.1080/ 14737159.2017.1356722.
Minh VN, Hau KT, Takashi M, et al. Efficacy of BCAF in monitoring treatment response in early vietnamese systemic sclerosis patients. Open Access Maced J. Med. Sci. 2019;7(2):264-268. DOI: 10.3889/ oamjms.2019.070.
Murdaca G, Spanò F, Contatore M, et al. Potential use of TNF- inhibitors in systemic sclerosis. Immunotherapy. 2014;6(3):283-289.
Nikpour M, Hissaria P, Byron J, et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: A cross-sectional analysis of data from an Australian cohort. Arthritis Res. Ther. 2011;13(6):211.
Ogawa F, Shimizu K, Hara T, et al. Serum levels of heat shock protein 70, a biomarker of cellular stress, are elevated in patients with systemic sclerosis: Association with fibrosis and vascular damage. Clin. Exp. Rheum. 2008;26:659-662.
Pardo A, Cabrera S, Maldonado M, Selman M. Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis. Respir. Res. 2016;17:23.
Rice LM, Mantero JC, Stifano G, et al. A proteome derived longitudinal pharmacodynamic biomarker for diffuse systemic sclerosis skin. J. Invest. Dermatol. 2017;137(1):62-70.
DOI: 10.1016/j. jid.2016.08.027.
Rice LM, Padilla CM, McLaughlin SR, et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J. Clin. Invest. 2015;125(7):2795-2807.
Rimar D, Rosner I, Nov Y, et al. Brief report: Lysyl oxidase is a potential biomarker of fibrosis in systemic sclerosis. Arthritis Rheum. 2014;66:726-730.
Rodnan GP, Lipinski E, Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum. 1979;22:130-140.
Said AH, Raufman JP, Xie G. The role of matrix metalloproteinases in colorectal cancer. Cancer (Basel). 2014;6(1):366-375.
DOI: 10.3390/ cancers6010366.
Van Bon L, Affandi AJ, Broen J, et al. Proteome-wide analysis and PLF4 as a biomarker in systemic sclerosis. N. Engl. J. Med. 2014;370:433-443.
Vira H, Pradhan V, Umare V, et al. Role of polymorphisms in MMP-9 and TICP-1 as biomarkers for susceptibility to systemic lupus erythematosus patients. Biomark. Med. 2019;13(1):33-43.
Abstract View: 39 times
PDF Download: 29 times